682 related articles for article (PubMed ID: 18199791)
1. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
[TBL] [Abstract][Full Text] [Related]
2. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
3. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Barton R; Bijie H; Bille J; Chang SC; da Luz Martins M; Duse A; Dzierzanowska D; Ellis D; Finquelievich J; Gould I; Gur D; Hoosen A; Lee K; Mallatova N; Mallie M; Peng NG; Petrikos G; Santiago A; Trupl J; VanDen Abeele AM; Wadula J; Zaidi M;
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
[TBL] [Abstract][Full Text] [Related]
4. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Mendez M; Kibbler C; Erzsebet P; Chang SC; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3551-6. PubMed ID: 17021081
[TBL] [Abstract][Full Text] [Related]
5. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
6. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):278-83. PubMed ID: 20846808
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Pfaller MA; Diekema DJ; Jones RN; Sader HS; Fluit AC; Hollis RJ; Messer SA;
J Clin Microbiol; 2001 Sep; 39(9):3254-9. PubMed ID: 11526159
[TBL] [Abstract][Full Text] [Related]
9. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Nagy E; Dobiasova S; Rinaldi M; Barton R; Veselov A;
J Clin Microbiol; 2008 Feb; 46(2):515-21. PubMed ID: 18077633
[TBL] [Abstract][Full Text] [Related]
10. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
11. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
12. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
14. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
[TBL] [Abstract][Full Text] [Related]
15. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
Jung SI; Shin JH; Song JH; Peck KR; Lee K; Kim MN; Chang HH; Moon CS;
Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
[TBL] [Abstract][Full Text] [Related]
16. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
[TBL] [Abstract][Full Text] [Related]
17. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
18. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
19. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
20. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
